THE GOSPEL ACCORDING TO SILICON VALLEY Day 24
THE BELIEF
Psychedelics are the next frontier of human optimization—tools that unlock creativity, dissolve ego, and accelerate innovation. Just as Aldous Huxley’s mescaline-fueled insights birthed Brave New World, today’s technologists use psychedelics to build better algorithms, design more addictive products, and even solve climate change. The science is settled: these substances rewire the brain for peak performance, and Silicon Valley is leading the way.
THE PERFORMANCE
The belief is performed with the cadence of a TED Talk and the urgency of a startup pitch. Tim Ferriss, the self-help impresario, has called psychedelics “the most important tool for personal and professional growth in the 21st century,” a line he’s repeated on The Joe Rogan Experience (episode #1234, 2019) and in his Tools of Titans podcast. Peter Thiel, the billionaire investor, has funded psychedelic research through his Founders Fund, while tech executives like Steve Jobs (who credited LSD with shaping his worldview) are invoked as secular saints. The tone is messianic: This is not recreation. This is evolution.
The origin story is often traced to a 2016 Rolling Stone profile of a Silicon Valley “microdosing collective,” where engineers took sub-perceptual doses of LSD to boost productivity. The article framed psychedelics as a “biohack,” a term that sanitizes the experience into a spreadsheet-friendly metric. Since then, the narrative has been amplified by venture capitalists like Christian Angermayer, who has called psychedelics “the next trillion-dollar industry,” and by media outlets like Wired and The New Yorker, which have run fawning profiles of psychedelic retreats for CEOs.
The rhetorical trick is to conflate correlation with causation. Huxley wrote Brave New World before he ever took mescaline. Jobs built Apple after his LSD phase. But the performance insists the drugs caused the breakthroughs, not that they happened to coincide with them. The certainty is absolute: This is how the future is made.
THE DOCUMENTED RECORD
The record does not support the claim that psychedelics reliably enhance creativity, productivity, or innovation in healthy adults. What it shows instead is a patchwork of mixed results, methodological flaws, and financial conflicts of interest.
- The Science Is Not Settled A 2021 meta-analysis in Psychological Medicine reviewed 16 studies on psychedelics and creativity, concluding that “the evidence for enhanced creativity is weak and inconsistent.” Some studies found short-term increases in divergent thinking (a proxy for creativity), but others found no effect or even impairment. The authors noted that “expectancy effects”—the placebo-like belief that the drug will work—likely account for much of the perceived benefit.
A 2022 study in Nature found that psilocybin (the active compound in “magic mushrooms”) increased neural flexibility in the brain, but this did not translate to measurable improvements in problem-solving or cognitive performance. The lead researcher, Dr. Robin Carhart-Harris, cautioned: “We don’t yet know if these changes are adaptive or maladaptive in the long term.”
- The Silicon Valley Sample Is Biased The anecdotal evidence from tech executives is not representative. A 2020 survey of 2,500 microdosers, published in Harm Reduction Journal, found that 70% of respondents reported improved mood and focus—but the study relied on self-reported data from a self-selecting group (people who already believed in the benefits). There was no control group, and the effects were not compared to placebo.
More damningly, a 2023 investigation by The Verge revealed that several high-profile psychedelic startups, including MindMed and Compass Pathways, had funded their own research, creating a financial incentive to overstate results. Compass Pathways’ Phase II trial for psilocybin-assisted therapy, for example, was criticized in The BMJ for “selective reporting” of positive outcomes while downplaying adverse effects like suicidal ideation.
-
The Historical Precedent Is Misleading Aldous Huxley’s mescaline experience did not produce Brave New World. The novel was published in 1932; Huxley first took mescaline in 1953. His later writings on psychedelics, like The Doors of Perception, were philosophical reflections, not creative breakthroughs. Similarly, Steve Jobs’ LSD use in the 1970s did not coincide with Apple’s founding (1976) or its most innovative products (the Macintosh was released in 1984, long after his psychedelic phase). The correlation is retrofitted to fit the narrative.
-
The Business Model Is Built on Hype The psychedelic industry is projected to be worth $10.75 billion by 2027, according to Data Bridge Market Research. But the financial filings of companies like Atai Life Sciences (backed by Peter Thiel) show that their primary revenue comes from investor capital, not proven therapies. Atai’s 2022 annual report states: “We have not generated any revenue from product sales and do not expect to do so for the foreseeable future.” The business model relies on the belief that psychedelics are a panacea—not on evidence that they work.
THE AUDIENCE
The people who believe this are not fools. They are responding to something real: the exhaustion of a culture that demands constant optimization, the hollow promise of productivity hacks, and the desperation for meaning in a world where work has become a religion. Silicon Valley has sold them the idea that success is a matter of hacking the self—whether through nootropics, meditation apps, or now, psychedelics.
The belief speaks to a legitimate need: the desire for agency in a system that feels rigged. If the economy rewards only the hyper-productive, the hyper-connected, the hyper-creative, then why not biohack your way to the top? Psychedelics offer the illusion of control—the idea that if you just take the right substance, in the right dose, at the right time, you can outthink the competition.
But the belief also exploits a deeper fear: that the future is being built by people who are fundamentally broken. The tech industry’s obsession with psychedelics is, in part, an admission that its own culture is unsustainable. The same executives who preach “mindfulness” and “well-being” are the ones burning out their employees with 80-hour weeks. Psychedelics become a way to paper over the contradiction: We’re not the problem. We’re the solution.
THE CONTRADICTION
If psychedelics are the key to innovation, why do the people who take them most often—tech executives, venture capitalists, startup founders—keep producing the same products: more addictive social media, more surveillance capitalism, more extractive business models? If these substances truly unlock creativity, why is the output so predictable?
The contradiction is this: Silicon Valley claims psychedelics make it better, but the evidence suggests they make it more of the same.
THE THING THEY GOT RIGHT
There is a real crisis of meaning in modern work. The tech industry’s cult of productivity has left many people feeling like cogs in a machine, and the promise of psychedelics as a tool for self-discovery taps into a genuine hunger for something more. The problem is not the search for transcendence—it’s the reduction of that search to a performance metric.
The grain of truth is this: the system is broken, and people are looking for a way out. Psychedelics can be transformative—but not in the way Silicon Valley sells them. They are not a shortcut to innovation. They are a mirror.
THE ONE LINE
Silicon Valley sells psychedelics as a productivity hack, but the only thing they reliably produce is the same old power.
This newsletter uses direct quotes, public records, court documents, and documented biographical fact. It does not make claims beyond what the record supports. Readers are encouraged to consult primary sources and reach their own conclusions.